What is the 13F Pro Quality Score for NGNE?

13F Pro ranks Neurogene Inc. (NGNE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NGNE's current score at https://13fpro.ai/research/NGNE (free sign-up required for the full ranking).

Which hedge funds own the most NGNE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NGNE include Samsara BioCapital,, Redmile Group,, Casdin Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NGNE as soon as new 13F filings post.

Where does 13F Pro source NGNE data?

All Neurogene Inc. fundamentals and ownership data come directly from SEC EDGAR. Neurogene Inc. files with the SEC under CIK 1404644. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NGNE in?

Neurogene Inc. (NGNE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NGNE research updated on 13F Pro?

NGNE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neurogene Inc.(NGNE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1404644 NGNE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NGNE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Neurogene Inc. (NGNE), a Healthcare sector company. NGNE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Neurogene Inc. reports net income of $-30.9M, free cash flow of $-26.4M. Top institutional holders of NGNE by reported 13-F value include Samsara BioCapital,, Redmile Group,, Casdin Capital,, based on the most recent SEC filings. NGNE trades on the Nasdaq exchange and files with the SEC under CIK 1404644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NGNE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neurogene Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-30.9M

Free Cash Flow

Q1 2026

$-26.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY22 —FY23 $0.00FY24 $925.0KFY25 $0.00

Net Income

-20.2% YoY

$-90.4MFY 2025

FY22 $-55.2MFY23 $-36.3MFY24 $-75.1MFY25 $-90.4M

Operating Income

-25.1% YoY

$-103.3MFY 2025

FY22 $-56.5MFY23 $-55.6MFY24 $-82.6MFY25 $-103.3M

EPS (Diluted)

+0.9% YoY

$-4.24FY 2025

FY22 $-1.04FY23 —FY24 $-4.28FY25 $-4.24

Total Assets

-14.0% YoY

$288.6MFY 2025

FY22 $109.3MFY23 $222.6MFY24 $335.7MFY25 $288.6M

Op. Cash Flow

-9.3% YoY

$-77.2MFY 2025

FY22 $-52.8MFY23 $-51.4MFY24 $-70.6MFY25 $-77.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$0.00 -100.0%	$925.0K	$0.00	—	—	—
Net Income	$-90.4M -20.2%	$-75.1M -106.9%	$-36.3M +34.2%	$-55.2M +9.1%	$-60.7M +12.6%	$-69.4M
Operating Income	$-103.3M -25.1%	$-82.6M -48.6%	$-55.6M +1.7%	$-56.5M +6.9%	$-60.7M +14.5%	$-71.0M
EPS (Diluted)	$-4.24 +0.9%	$-4.28	—	$-1.04 +5.5%	$-1.10	—
Total Assets	$288.6M -14.0%	$335.7M +50.8%	$222.6M +103.7%	$109.3M -33.1%	$163.3M +11.0%	$147.0M
Operating Cash Flow	$-77.2M -9.3%	$-70.6M -37.3%	$-51.4M +2.7%	$-52.8M -11.1%	$-47.6M -208.9%	$-15.4M

AI Insight: NGNE Financial Trends

Neurogene's cash burn accelerated sharply in Q1 2026, with operating losses hitting a new high of $33M while equity eroded to $238M.

• Operating losses widened from $20M in Q2 2024 to $33M in Q1 2026, a 65% deterioration over seven quarters.

• Equity declined from a Q4 2024 peak of $310M to $238M in Q1 2026, a $72M drawdown in three quarters.

• Operating cash outflow reached $26M in Q1 2026, the largest single-quarter burn in the observable period.

⚠ At the Q1 2026 burn rate of ~$26M/quarter, the $238M equity base implies a limited cash runway without new financing.

⚠ No debt is reported across all periods; monitor whether the company taps debt markets as equity erodes further.

AI Insight: NGNE Ratio Trends

NGNE's return metrics are deteriorating sharply in Q1 2026, with ROIC hitting -56.1% — the worst single-quarter reading in the dataset outside Q3 2024.

• ROIC worsened dramatically from -35.9% in Q3 2025 to -56.1% in Q1 2026, a 20pp deterioration in one quarter.

• ROE fell from -31.6% in Q3 2025 to -52.0% in Q1 2026, matching the steep losses seen in Q3 2024.

• TTM ROIC of -46.6% is less severe than the Q1 2026 quarterly reading of -56.1%, suggesting recent burn acceleration.

⚠ Q1 2026 ROIC of -56.1% is the sharpest quarterly deterioration since Q3 2024 — monitor whether this reflects a one-off spend spike.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods, leaving capital structure and revenue visibility opaque.

Get alerted when NGNE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neurogene Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NGNE

Samsara BioCapital, LLC
$34.6M1,717,127 sh
Redmile Group, LLC
$29.4M1,459,599 sh
Casdin Capital, LLC
$28.6M1,420,361 sh
RTW INVESTMENTS, LP
$27.5M1,362,456 sh
EcoR1 Capital, LLC
$25.6M1,271,342 sh
BlackRock, Inc.
$20.3M1,005,070 sh
BAKER BROS. ADVISORS LP
$20.0M991,691 sh
Trails Edge Capital Partners, LP
$15.8M782,787 sh
BALYASNY ASSET MANAGEMENT L.P.
$14.5M718,389 sh
TORONTO DOMINION BANK
$13.7M681,337 sh

Fund	Value	Shares
Samsara BioCapital, LLC	$34.6M	1,717,127
Redmile Group, LLC	$29.4M	1,459,599
Casdin Capital, LLC	$28.6M	1,420,361
RTW INVESTMENTS, LP	$27.5M	1,362,456
EcoR1 Capital, LLC	$25.6M	1,271,342
BlackRock, Inc.	$20.3M	1,005,070
BAKER BROS. ADVISORS LP	$20.0M	991,691
Trails Edge Capital Partners, LP	$15.8M	782,787
BALYASNY ASSET MANAGEMENT L.P.	$14.5M	718,389
TORONTO DOMINION BANK	$13.7M	681,337

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NGNE on your watchlist

Track score changes the day Neurogene Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NGNE a good stock to buy?

13F Pro's AI-powered analysis of Neurogene Inc. (NGNE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NGNE are available on the NGNE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NGNE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NGNE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neurogene Inc.'s investment landscape.